SCHEMBL2960195

SCHEMBL2960195

CCOC(=O)c1sc2c(ccc(=O)n2-c2ccccc2)c1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
MAPT P10636 7/20 0.52
KDM4E B2RXH2 6/20 0.52
HPGD P15428 6/20 0.52
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
GAA P10253 4/20 0.47
POLB P06746 2/20 0.47
MDM2 Q00987 1/20 0.47
HSD17B10 Q99714 5/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
RECQL P46063 1/20 0.44
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MAT2A P31153 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474394 0.88 MAPT (0.54) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL1265759 0.86 MAPT (0.52) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL5648517 0.85 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL5650136 0.85 MAPT (0.51) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL2783455 0.84 MAPT (0.50) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL3835945 0.83 MAPT (0.49) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL3117392 0.83 ALDH1A1 (0.54) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL3833709 0.83 MAPT (0.49) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL1266606 0.83 MAPT (0.49) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL3144851 0.83 ALDH1A1 (0.55) ALDH1A1MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20100179185-A1 Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof UCB PHARMA, S.A. (BE) 2010-07-15 US disclosed
US-7592455-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2009-09-22 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7482452-B2 Process for preparing 3-aminothienopyridone derivatives CELLTECH R&D LIMITED (GB) 2009-01-27 US disclosed
EP-1638980-B1 PROCESS FOR PREPARING 3-AMINOTHIENOPYRIDONE DERIVATIVES UCB PHARMA SA (BE) 2008-11-05 EP disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20070191608-A1 Process for preparing 3-aminothienopyridone derivatives CELLTECH R&D LIMITED (GB) 2007-08-16 US disclosed
US-20060025428-A1 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA S.A. (BE) 2006-02-02 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed
EP-1539769-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS Celltech R & D Limited (GB) 2005-06-15 EP disclosed
WO-2004014920-A1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS CELLTECH R & D LIMITED (GB) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179185-A1 Novel Aminothienopyridinone Derivatives Processes for Preparing Them and Pharmaceutical Compositions Thereof AASDHPPT, PTMS, TPMT ALDH1A1 1775/4885MEN1 920/4885KMT2A 1979/4885
US-20070191608-A1 Process for preparing 3-aminothienopyridone derivatives MAPK3, MAP3K6, MAP4K1 ALDH1A1 1970/4885MEN1 3935/4885KMT2A 1464/4885
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK ALDH1A1 1045/4885MEN1 4273/4885KMT2A 1316/4885
US-20060025428-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K6 ALDH1A1 3847/4885MEN1 4813/4885KMT2A 2011/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 ALDH1A1 717/4885MEN1 3906/4885KMT2A 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.